COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

pK of a Novel 200 mg Ibuprofen Medicated Plaster

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03694587
Recruitment Status : Completed
First Posted : October 3, 2018
Last Update Posted : April 16, 2019
Cooperative Clinical Drug Research and Development AG (CCDRD AG)
Information provided by (Responsible Party):
Medherant Ltd

Brief Summary:

This is a Phase I study of the pharmacokinetics of a novel 200 mg Ibuprofen Medicated Plaster. The study will be conducted as a monocentric, open, randomised, single and multiple-dose, two-period, crossover trial in healthy volunteers. A total of 16 healthy volunteers will be randomised.

A wash-out period of 3 days is planned between the two periods. Each of the volunteers will be randomly assigned to one of 2 possible administration sequences.

Condition or disease Intervention/treatment Phase
Healthy Drug: Ibuprofen 200 mg TEPI Medicated Plaster Drug: Aktren® 200 mg überzogene Tabletten (Ibuprofen) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single and Multiple Dose, Randomised, Open-label, Cross-over, Healthy Volunteer, Phase I Study of the Pharmacokinetics of a Novel 200 mg Ibuprofen Medicated Plaster
Actual Study Start Date : September 25, 2018
Actual Primary Completion Date : October 18, 2018
Actual Study Completion Date : October 18, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Test IMP Drug: Ibuprofen 200 mg TEPI Medicated Plaster
Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days

Active Comparator: Reference IMP Drug: Aktren® 200 mg überzogene Tabletten (Ibuprofen)
one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)

Primary Outcome Measures :
  1. AUC(0-12h) of ibuprofen [ Time Frame: 5 days ]
    Area under the concentration/time curve, from time 0 h to 12 h

  2. AUC(0-t) of Ibuprofen [ Time Frame: 5 days ]
    Area under the concentration/time curve, calculated by the trapezoidal rule from time 0 h to last observed concentration at time t

  3. Cmax of Ibuprofen [ Time Frame: 5 days ]
    Observed maximal concentration after administration

Secondary Outcome Measures :
  1. Tmax after multiple dosing [ Time Frame: 5 days ]
    Observed time point of maximal concentration

  2. t½ after multiple dosing [ Time Frame: 5days ]
    Plasma concentration half-life calculated according to t1/2=ln(2)/ λz

  3. λz of total ibuprofen after multiple dosing [ Time Frame: 5 days ]
    Terminal rate constant (slowest rate constant of the disposition) negative of the slope of a log-linear regression of the unweighted data considering the last concentration-time points ≥ LLOQ

  4. AUC(0-inf) after multiple dosing [ Time Frame: 5 days ]
    Area under the concentration/time curve, from time 0 h extrapolated to infinity (AUC(0-∞) = AUC(0-t) + Clast/λz where Clast is the last concentration above the limit of quantification and λz is the terminal elimination constant)

Other Outcome Measures:
  1. AUC(0-τ) After plaster removal, [ Time Frame: 5 days ]
    Area under the concentration/time curve, from time 0 h the end of the treatment period

  2. Number of subjects with product related Adverse Events [ Time Frame: 15 days ]
    Adverse events from subject informed consent until the follow-up call

  3. Change in dermal effect score to baseline [ Time Frame: 15 days ]

    Skin irritation by using "Dermal Effect Score" and "Other Effect Score") Dermal Response Score Score Definition 0- No evidence of irritation

    1. - Minimal erythema, barely perceptible
    2. - Definite erythema, readily visible; minimal oedema or minimal papular
    3. - Erythema and papules
    4. - Definite oedema
    5. - Erythema, oedema, and papules
    6. - Vesicular eruption
    7. - Strong reaction spreading beyond test site

    Score Definition 0 - None observed

    1. - Slight glazed appearance
    2. - Marked glazing
    3. - Glazing with peeling and cracking
    4. - Glazing with fissures. Film of dried serous exudates covering all or part of the patch site Small petechial erosions and/or scabs

  4. Abnormal laboratory findings [ Time Frame: 15 days ]
    Abnormal laboratory findings with respect to the pre-defined reference ranges

  5. Adhesion (quantitative, using the mean adhesion score) and qualitative assessment of the plaster [ Time Frame: Day 1 and Day 5 ]

    The percentage of the Ibuprofen 200 mg TEPI plaster adhered to the skin will be assessed at the following time points on application of plaster 1 and plaster 5: at placement of plaster (T0) and then at the following time points post placement: 4, 8, 12, 16, 20 and 24 hours. An adhesion score will be assigned using a 5-point numerical scale 0 = ≥ 90% adhered (essentially no lifting off the skin)

    1. = ≥ 75% to < 90% adhered (some edges only lifting off the skin)
    2. = ≥ 50% to < 75% adhered (less than half of the plaster lifting off the skin)
    3. = > 0% to < 50% adhered (not detached, but more than half of the plaster lifting off the skin without falling off)
    4. = 0% adhered (plaster detached; completely off skin)

  6. Cmax, ss after plaster removal [ Time Frame: 5 days ]
    Observed maximal concentration after administration at steady state

  7. CT, ss after plaster removal [ Time Frame: 5 days ]
    Observed maximal concentration after administration at the end of τ at steady state

  8. residual ibuprofen in removed plasters [ Time Frame: 5 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female subject
  • Age between 18 and 65 years
  • Physically and mentally healthy as judged by means of medical and standard laboratory examinations
  • Non-smokers or ex-smokers (stopped at least 6 months ago) with a smoking history of ≤5 pack-year equivalents (1 pack-year equivalent is equal to smoking 1 pack per day for 1 year**) and non-users of other nicotine containing products, confirmed by urine cotinine test
  • Weight ≥ 60 kg and BMI within the range (including the borders)1 of 18.0 to 30.0 kg/m2
  • Informed consent given in written form according to chapter 5.4 of the study protocol

Exclusion Criteria:

  • Participation in another clinical trial at same time or within the preceding 90 days (calculated from the date of the final examination of the previous study)
  • Fertile women without reliable contraception method. List of medically accepted contraceptive methods (used at least 4 weeks prior entry screening visit and not to be changed for the duration of the study):

    • combination of 2 barrier methods: female/male condoms, diaphragms, spermicides
    • voluntary sterilization (female tubal occlusion).
  • Randomisation into the present trial more than once
  • Blood donation or blood loss including plasmapheresis of >500 ml in the last 90 days before entry screening
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at entry screening
  • History of drug abuse or use of illegal drugs: use of soft drugs, e.g. marihuana within 6 months of entry screening or hard drugs, e.g. cocaine, amphetamines, phencyclidine within 1 year before entry screening
  • Alcohol abuse, i.e. regular use of more than 2 units of alcohol per day or 10 units per week or a history of alcoholism (one unit of alcohol equals 250 ml beer, 125 ml wine or 25 ml spirits) or recovered alcoholics
  • Regular consumption of beverages or food containing methylxanthines (e.g. coffee, tea, cola, caffeine containing sodas, chocolate) equivalent to more than 500 mg methylxanthines per day
  • Positive drug screening and/or positive alcohol test at entry screening or on hospitalization day -1
  • Pregnant and/or nursing women. Positive pregnancy test at entry screening or on hospitalization day -1
  • Allergic diathesis or any clinically significant allergic disease (i.e. asthma or bronchial hyperreactivity)
  • Known allergy to sticking plaster or to the ingredients of the products
  • History of or active skin disease or dermatologic disease that might interfere with the evaluation of test site reaction
  • Any history of drug hypersensitivity (especially to the active and inactive ingredients of the ibuprofen preparations and NSAIDs including subjects where attacks of asthma, angioedema, urticaria or rhinitis have been precipitated), or intolerance to any sugar (e.g. fructose, glucose, or lactose)
  • History of clinically significant food allergies or current significant or perennial allergy at screening
  • History of autoimmune disorders such as lupus erythematosus
  • Presence or a history of clinically significant cardiovascular, renal, hepatic, pulmonary, metabolic, endocrine, haematological, gastrointestinal, neurological, psychiatric or other diseases
  • Clinically significant illness within 4 weeks before entry screening and during the study
  • Major surgery of the gastrointestinal tract except for appendectomy
  • Any chronic disease which might interfere with absorption, distribution, metabolism or excretion of the drug
  • Intensive UV-light exposure (sunbaths) at the application site or use of tanning beds within 2 weeks before entry screening and during the study
  • Intake or administration of any systemic or any topical medication (including immune system interfering drugs, OTC medication and especially intake of antacids e.g. aluminum hydroxide, magnesium hydroxide, and simethicone or herbal medication e.g. St. John's wort, kava kava, or use of ointments, gels or patches for skin application, piperine containing products16) as well as hormone replacement therapy within 2 weeks before entry screening and during the study, except single doses of paracetamol given in case of an adverse event (e.g. headache) during the study
  • Use of topical products without medication at the application sites (including make-up, sunscreen, creams, lotions, powders, alcohol) 7 days prior to entry screening until discharge
  • Administration of depot injectable solutions or medications with a half-life > 1 week (including study medications) within 6 months before entry screening
  • Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before entry screening
  • Medication with drugs known to alter the major organs or systems such as barbiturates, phenothiazines, cimetidine, omeprazole etc. within the last 2 months prior entry screening
  • Any method of hair removal (e.g. waxing, shaving, epilating, laser) at the application sites 7 days prior to entry screening until discharge
  • Subjects with tattoos, sunburn, coloration, open sores or scars (e.g. any burning or stinging) on site(s) of application
  • History of difficulty in swallowing
  • Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies
  • Systolic blood pressure outside the range of 100 to 140 mmHg and/or diastolic blood pressure outside the range of 60 to 90 mmHg17 at entry screening visit
  • Heart rate outside the range of 50 to 90 beats/min at entry screening visit
  • Respiratory rate outside the range of 12-24 breaths/min at entry screening visit
  • Axillary body temperature outside the interval of 35.5 to 37.1°C at entry screening visit
  • Any clinically significant abnormality of the resting ECG (12-lead) (i.e. AV block, 2° to 3°, sinus bradycardia, sick sinus syndrome, SA block)
  • Laboratory values outside normal range with clinical relevance at entry screening visit
  • Vomiting within the first 4 hours after dosing with oral ibuprofen
  • Diarrhoea within the first 24 hours after dosing with oral ibuprofen
  • Special diet due to any reason, e.g. vegetarians
  • Not fulfilling study specific restrictions given in a study protocol
  • Engagement in strenuous exercise within 2 weeks prior to check-in (e.g., marathon runners, weight lifters)
  • Subjects who are known or suspected:

    • not to comply with the study directives
    • not to be reliable or trustworthy
    • not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent), in particular regarding the risks and discomfort to which they would agree to be exposed
    • to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the inconvenience they may be involved in
    • subject is a dependent person, e.g. a relative, family member, or member of the investigator's or sponsor's staff
    • subject is in custody or submitted to an institution due to a judicial order.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03694587

Layout table for location information
Clinic of Clinical Pharmacology and Therapeutics University Multidisciplinary Hospital for Active Treatment 'Tsaritsa Ioanna-ISUL' EAD
Sofia, Bulgaria, 1504
Sponsors and Collaborators
Medherant Ltd
Cooperative Clinical Drug Research and Development AG (CCDRD AG)

Layout table for additonal information
Responsible Party: Medherant Ltd Identifier: NCT03694587    
Other Study ID Numbers: MED-IBU-101
First Posted: October 3, 2018    Key Record Dates
Last Update Posted: April 16, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action